---
title: "Cantor Fitzgerald Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301267610.md"
description: "Cantor Fitzgerald analyst Carter Gould maintained a Hold rating on Bristol-Myers Squibb (BMY) with a $53.00 price target. This follows mixed sentiment from other firms: Leerink Partners also issued a Hold, while Morgan Stanley assigned a Sell rating to the stock on the same day."
datetime: "2026-10-08T11:25:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301267610.md)
  - [en](https://longbridge.com/en/news/301267610.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301267610.md)
generator: "portal-rs"
---

# Cantor Fitzgerald Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

In a report released today, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Bristol-Myers Squibb, with a price target of $53.00.

Gould covers the Healthcare sector, focusing on stocks such as Amgen, Bristol-Myers Squibb, and Eli Lilly & Co. According to TipRanks, Gould has an average return of 6.4% and a 53.19% success rate on recommended stocks. 

In addition to Cantor Fitzgerald, Bristol-Myers Squibb also received a Hold from Leerink Partners’s David Risinger in a report issued yesterday. However, on the same day, Morgan Stanley assigned a Sell rating to Bristol-Myers Squibb (NYSE: BMY).

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)

## Related News & Research

- [Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause](https://longbridge.com/en/news/302909326.md)
- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [BUZZ-Bristol Myers rises on positive trial results for cancer and lung disease drugs](https://longbridge.com/en/news/301590676.md)
- [Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial](https://longbridge.com/en/news/301263394.md)
- [Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%](https://longbridge.com/en/news/301304214.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**